Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cypher, Taxus Perform Equally Well In Trials, Registries – Meier Analysis

This article was originally published in The Gray Sheet

Executive Summary

The overall clinical performance of Boston Scientific's Taxus and J&J/Cordis' Cypher drug-eluting coronary stents is practically equivalent, according to Bernard Meier, MD, University Hospital, Bern, Switzerland

You may also be interested in...



REALITY delayed

Johnson & Johnson/Cordis will announce results of its REALITY trial, comparing Cypher sirolimus-eluting stents with Boston Scientific Taxus paclitaxel-eluting stents, at the American College of Cardiology meeting in March in Orlando, instead of at the November American Heart Association meeting in New Orleans, as previously planned, the firm announced Sept. 14 (1"The Gray Sheet" May 10, 2004, p. 6)...

REALITY delayed

Johnson & Johnson/Cordis will announce results of its REALITY trial, comparing Cypher sirolimus-eluting stents with Boston Scientific Taxus paclitaxel-eluting stents, at the American College of Cardiology meeting in March in Orlando, instead of at the November American Heart Association meeting in New Orleans, as previously planned, the firm announced Sept. 14 (1"The Gray Sheet" May 10, 2004, p. 6)...

FDA stays tuned to Taxus adverse events

Agency pledges to keep the public apprised of complaints related to the Boston Scientific paclitaxel-eluting stent, but says collected data detailing 28 Taxus incidents to date are insufficient to justify a formal solicitation similar to last October's "web notification" about J&J/Cordis' Cypher thrombosis rates. Some physicians have reported that the Taxus delivery system resists extraction after stent deployment, possibly due to improper balloon deflation. The incident rate is about 11.8 complaints per 1,000 used, Boston Scientific says, attributing the problems to physicians unfamiliar with the system (1"The Gray Sheet" April 26, 2004, p. 5)...

Related Content

UsernamePublicRestriction

Register

MT020184

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel